Summary
Healthcare company Provalis has won regulatory approval in the US for a new diabetes testing kit. Shares in the Deeside company climbed by more than a quarter in early trading after announcing to the Stock Exchange that it had won regulatory approval from the Food and Drug Administration for its In2it testing system for the monitoring of diabetes. The kit also received prescription home-use approval.
Provalis said the approval would allow it to fully exploit the US sales potential of In2it through doctors' surgeries.See the full content of this document
Extract
Us Nod for Provalis' Diabetes Kit
Provalis Diagnostics US will now begin promot...
See the full content of this document
Sponsored links
